Dr Reddy’s on Friday mentioned its energetic pharmaceutical ingredient (API) manufacturing facility in Bollaram, Hyderabad (CTO-3), accomplished US Food & Drug Administration (USFDA)’s GMP (good manufacturing practices) inspection with zero observations.
The inspection was carried out from June 12, 2023 to June 16, 2023.
The firm additionally mentioned it has obtained institution inspection report (EIR) for its formulations manufacturing unit in Srikakulam (FTO SEZ PU2), Andhra Pradesh.
EIR means closure of inspection.
The Agency has labeled the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is “closed”, the corporate mentioned in a press release to inventory exchanges.
The profitable clearance of GMP inspection will allow Dr Reddy’s to launch new product and mitigate impression of worth.
